These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32442860)

  • 1. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases.
    Thomas de Montpréville V; Lacroix L; Rouleau E; Mamodaly M; Leclerc J; Tutuianu L; Planchard D; Boulate D; Mercier O; Besse B; Fadel É; Ghigna MR
    Ann Diagn Pathol; 2020 Jun; 46():151522. PubMed ID: 32442860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
    Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
    PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
    Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.
    Kunishige M; Takeuchi E
    Thorac Cancer; 2023 Dec; 14(34):3419-3420. PubMed ID: 37920971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
    Ho HL; Kao HL; Yeh YC; Chou TY
    Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive Patterns of CTNNB1 (β-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
    Jo VY; Sholl LM; Krane JF
    Am J Surg Pathol; 2016 Aug; 40(8):1143-50. PubMed ID: 27259009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
    Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
    Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
    Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
    Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
    Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.
    Skov BG; Høgdall E; Clementsen P; Krasnik M; Larsen KR; Sørensen JB; Skov T; Mellemgaard A
    APMIS; 2015 Feb; 123(2):108-15. PubMed ID: 25421919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
    Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
    Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.